Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

MammaPrint Interpreter

MammaPrint analyzes 70 genes to determine the risk of breast cancer recurrence.

Evidence-based context for fast calculator use

Purpose:
MammaPrint Interpreter classifies 70-gene breast cancer assay results to guide chemotherapy de-escalation decisions per MINDACT trial data.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
MammaPrint Result, Clinical Risk
Reference:
Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717-729.
HomeMammaPrint Interpreter
Pin your most used calculators here by clicking the star in the dropdown.

MammaPrint Interpreter

Clinical Context & Background

MammaPrint analyzes 70 genes to determine the risk of breast cancer recurrence. The MINDACT trial demonstrated its utility in de-escalating chemotherapy in patients who are clinically high risk but genomically low risk.
Primary Source EvidenceCardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717-729.
Formula Logic
Binary classification: Low Risk vs High Risk.

Reference Data

Result5-Year DMFS (No Chemo)Recommendation
Low Risk> 95%Chemotherapy can typically be omitted (MINDACT).
High Risk< 90%Chemotherapy recommended.

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use MammaPrint Interpreter when mammaPrint Interpreter classifies 70-gene breast cancer assay results to guide chemotherapy de-escalation decisions per MINDACT trial data.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify MammaPrint Result, Clinical Risk, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should MammaPrint Interpreter be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can MammaPrint Interpreter determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.